HIV-1 Nef promotes survival of myeloid cells by a Stat3-dependent pathway by Briggs, Scott D. et al.
HIV-1 Nef Promotes Survival of Myeloid Cells by a
Stat3-dependent Pathway*
Received for publication, April 11, 2001, and in revised form, April 24, 2001
Published, JBC Papers in Press, April 27, 2001, DOI 10.1074/jbc.M103244200
Scott D. Briggs‡, Beata Scholtz§, Jean-Marc Jacque¶, Simon Swingler¶, Mario Stevenson¶, and
Thomas E. Smithgalli
From the Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh,
Pennsylvania 15261 and the ¶Program in Molecular Medicine, University of Massachusetts Medical Center,
Worcester, Massachusetts 01605
Human immunodeficiency virus Nef is a small my-
ristylated protein that plays a critical role in AIDS pro-
gression. Nef binds with high affinity to the SH3 domain
of the myeloid-restricted tyrosine kinase Hck in vitro,
identifying this Src-related kinase as a possible cellular
target for Nef in macrophages. Here we show that Nef
activates endogenous Hck in the granulocyte-macro-
phage colony-stimulating factor-dependent myeloid cell
line, TF-1. Unexpectedly, Nef induced cytokine-inde-
pendent TF-1 cell outgrowth and constitutive activation
of the Stat3 transcription factor. Induction of survival
required the Nef SH3 binding and membrane-targeting
motifs and was blocked by dominant-negative Stat3 mu-
tants. Nef also stimulated Stat3 activation in primary
human macrophages, providing evidence for Stat3 as a
Nef effector in a target cell for human immunodefi-
ciency virus.
nef is a highly conserved gene unique to the primate lentivi-
ruses HIV-1,1 HIV-2, and SIV (1, 2). Previous studies show that
Nef is required for high titer replication of HIV and SIV and
greatly accelerates the development of AIDS-like disease in
Rhesus monkeys (3). HIV strains with defective nef alleles have
been isolated from patients with long term, non-progressive
HIV infection, implicating nef as a progression factor in AIDS
(4, 5). Although nef is not required for the growth of HIV in
most cultured cell lines, it has been shown to enhance HIV
replication in resting peripheral blood mononuclear cells (6, 7).
Furthermore, selective expression of nef in T-cells and mono-
cytes/macrophages of transgenic mice is sufficient to induce a
severe AIDS-like syndrome (8). However, the molecular mech-
anisms by which nef contributes to the replication and patho-
genicity of HIV and SIV are not clear.
The nef gene encodes a 25–30-kDa myristylated protein with
no identified catalytic activity and is believed to influence cel-
lular signaling pathways by physically interacting with host
cell proteins and modifying their functions (1, 2). In particular,
non-receptor tyrosine kinases of the Src family have emerged
as potential intracellular targets for Nef. Like Nef, Src family
kinases are also myristylated and localize to cellular mem-
branes (9). The SH3 domain of the Src-related kinase Hck
binds to Nef with the highest affinity known for an SH3-
mediated interaction (10, 11). Mutagenesis has established
that the Nef motif responsible for SH3 binding consists of the
repeated proline-rich sequence PXXPXXPXXP, where X 5 any
amino acid (10). X-ray crystallographic and NMR structural
studies of high affinity SH3-Nef complexes show that these
residues form the polyproline type II helix responsible for most
SH3-mediated interactions (12, 13). The Nef PXXP motif is
highly conserved among known HIV isolates (14) and is impor-
tant for SIV replication in macaques (3). These findings sup-
port the notion that the SH3 binding function of Nef and its
interaction with Hck or other Src family members are essential
to its functions in HIV replication and AIDS progression.
Recently, we reported that SH3-dependent interaction with
Nef functionally activates full-length Hck in Rat-2 fibroblasts,
leading to cellular transformation (15–17). In addition, we
demonstrated that this transformation event correlates with
increased cellular phosphotyrosine content and NefzHck com-
plex formation, suggesting that Nef directly activates Hck in
vivo. In the present study, we extend these findings by showing
that Nef activates endogenous Hck in the cytokine-dependent
monocyte/macrophage precursor cell line, TF-1 (18). Surpris-
ingly, Nef produced a cytokine-independent phenotype in these
cells that requires the Nef SH3 binding motif and myristylation
signal sequence. Nef also induced constitutive activation of the
Stat3 transcription factor in the cytokine-independent TF-1
cells, providing further evidence for the activation of endoge-
nous Hck or a closely related tyrosine kinase by Nef. Experi-
ments with dominant-negative Stat3 mutants indicate that
Nef-induced TF-1 survival is dependent upon Stat3 activation.
Nef also induced Stat3 activation in primary human macro-
phages. These results show for the first time that Nef can
activate endogenous Src family kinases and downstream Stat
factors in a cell lineage relevant to HIV infection.
EXPERIMENTAL PROCEDURES
Cell Culture—The human myeloid leukemia cell line TF-1 (18) was
obtained from the American Type Culture Collection (ATCC) and grown
in RPMI 1640 medium supplemented with 10% fetal bovine serum, 50
mg/ml gentamycin, and 3 3 105 units/ml recombinant human GM-CSF
(a generous gift of the Immunex Corp.). The human cell line 293T (19)
was also obtained from the ATCC and grown in Dulbecco’s modified
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Eagle’s medium containing 5% fetal bovine serum and 50 mg/ml
gentamycin.
Hck and Nef Expression Constructs—The nef gene used in these
studies is from the HIV-1 isolate SF2. The Nef mutants used include
Nef-PA, in which Pro residues 72 and 75 were converted to Ala, and
Nef-GA, in which the Gly residue at position 2 was converted to Ala.
Both mutants were produced using standard polymerase chain reac-
tion-based methods and subcloned along with wild-type Nef into the
retroviral vector pSRaMSVtkneo (20). The resulting constructs were
used to generate high titer stocks of recombinant retroviruses by co-
transfection of 293T cells with an amphotropic packaging vector as
described elsewhere (15–17, 21).
Construction of activated (Y501F) and kinase-dead (K269E) Hck
mutants is described elsewhere (15, 22). These mutants together with
wild-type Hck were subcloned into the mammalian expression vector
pCDNA3 (InVitrogen) for transient expression in 293T cells. The
pCDNA3-based expression vector for Stat3 has been described else-
where (23).
The Stat3 dominant-negative mutant Stat3-EVA was supplied by
Dr. Richard Jove, Moffitt Cancer Center. A point mutation converting
Tyr-705 of murine Stat3 to Phe (Stat3-YF) was introduced into
pcDNA3-Stat3 using the GeneEditor in vitro site-directed mutagenesis
system (Promega). The dominant-negative Stat3 mutants were sub-
cloned into a variant of the retroviral vector pSRaMSVtkneo in which
the neo-antibiotic resistance marker was replaced by a DNA fragment
coding for the hygromycin-resistance gene. The resulting plasmids were
used to make recombinant retroviruses in 293T cells as described
above.
Soft Agar Colony Assay—TF-1 cells were infected with recombinant
Nef retroviruses using a centrifugal enhancement procedure described
elsewhere (24). Briefly, TF-1 cells (5 3 104) were resuspended in retro-
viral supernatants and centrifuged at 1,000 3 g for 4 h in the presence
of 4 mg/ml Polybrene. After selection with G418 in the presence of
GM-CSF, 1 3 104 drug-resistant cells were plated in triplicate 35-mm
dishes in RPMI 1640 medium containing 0.3% agar and 20% fetal
bovine serum in the presence and absence of GM-CSF. Colony forma-
tion was assessed 2 weeks later.
Cell Lysis and Immune Complex Kinase Assay—TF-1 cells (106) were
incubated in the absence of GM-CSF for 48 h and then lysed in 1.0 ml
of modified radioimmune precipitation buffer (50 mM Tris-HCl, pH 7.4,
50 mM NaCl, 1 mM EDTA, 10 mM MgCl2, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS). TF-1 cell lysates were clarified by centrifuga-
tion at 100,000 3 g for 30 min at 4 °C. Clarified cell lysates were
incubated with rabbit antibodies to Hck or Fyn (Santa Cruz Biotech-
nology) and protein G-Sepharose (20 ml of a 50% slurry) for 2 h at 4 °C.
The kinase immunoprecipitates were collected by centrifugation and
washed twice with 1.0 ml of radioimmune precipitation buffer followed
by two washes with kinase buffer (50 mM HEPES, pH 7.4, 10 mM
MgCl2). Kinase buffer (20 ml) containing 1 mg of the p50 substrate
(50-kDa glutathione S-transferase-Sam 68 fusion protein; Santa Cruz
Biotechnology) and 5 mCi [g-32P]ATP (3,000 Ci/mmol; PerkinElmer Life
Sciences) was added to the washed immunoprecipitates and incubated
for 15 min at 30 °C. Reactions were quenched by adding SDS-polyacryl-
amide gel electrophoresis sample buffer and heating to 95 °C for 5 min.
Proteins were resolved by SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride, and levels of the immunopre-
cipitated kinases were visualized by immunoblotting with monoclonal
antibodies to Hck or Fyn (Transduction Laboratories). Radiolabeled p50
was visualized and quantitated by storage phosphor technology (Molec-
ular Dynamics PhosphorImager).
Electrophoretic Mobility Shift Assay—TF-1 or 293T cells were
washed once with phosphate-buffered saline containing 1 mM Na3VO4
and 5 mM NaF. Cells were resuspended with 0.5 ml of hypotonic buffer
(40 mM HEPES, pH 7.9, 2 mM EDTA, 2 mM EGTA, 20 mM NaF, 1 mM
Na3VO4, 1 mM Na4P2O7, 1 mM dithiothreitol, 0.5 mM phenylmethylsul-
fonyl fluoride, 50 mg/ml leupeptin, 25 mg/ml aprotinin, and 150 mM
Na2MoO4), sonicated for 10 s, and then centrifuged for 30 s at 14,000
rpm and 4 °C. Nuclei were resuspended in high salt buffer (40 mM
HEPES, pH 7.9, 840 mM NaCl, 2 mM EDTA, 2 mM EGTA, 40% glycerol,
20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride, 50 mg/ml leupeptin, 25 mg/ml aprotinin,
and 150 mM Na2MoO4) and incubated for 30 min on a rotator at 4 °C.
Nuclear extracts were clarified by microcentrifugation for 5 min at
14,000 rpm and 4 °C. The protein concentrations of the nuclear extracts
were determined using the Coomassie Plus protein assay reagent
(Pierce) and bovine serum albumin as standard. For the gel-shift assay,
10 mg of TF-1 and 5 mg of 293T nuclear extracts were used. The probe
used for the Stat3 gel-shift assay is based on the sis-inducible element
(SIE) (25). Oligonucleotides (20 pmol) were annealed in 10 ml of TE
buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) by heating to 70 °C and
slowly cooling to room temperature. The probes were labeled by com-
bining 4 ml of annealed oligonucleotide with 2 ml of Labeling Mix-dATP
(Amersham Pharmacia Biotech), 2 ml of [g-32P]dATP (10mCi/ml; Amer-
sham Pharmacia Biotech), and 2 ml of the Klenow fragment of DNA
polymerase (Life Technologies, Inc., 3.7 units/ml). The mixture was
incubated at room temperature for 30 min, and the unincorporated
nucleotides were removed using a G-25 Sephadex spin column (Milli-
pore). DNA binding reactions contained 40,000 cpm of labeled probe in
a final volume of 20 ml. Reactions were incubated at 30 °C for 30 min
and run on 5% polyacrylamide gels in 0.253 Tris borate-EDTA buffer.
Gels were fixed with 10% acetic acid, 10% methanol, rinsed with water,
dried, and exposed to a storage phosphor screen. Images were visual-
ized using a Molecular Dynamics PhosphorImager.
Expression of Hck and STAT3 in 293T Cells—Human 293T cells
were transfected with Hck and Stat3 expression plasmids using a
calcium phosphate-mediated transfection procedure described else-
where (26). Cells were lysed in modified radioimmune precipitation
buffer, and Stat3 expression and tyrosine phosphorylation were de-
tected by immunoblotting with antibodies to phosphotyrosine or Stat3
(Santa Cruz Biotechnology). Control blots were performed with anti-
Hck antibodies (Santa Cruz) to verify Hck expression.
Primary Macrophage Culture, Adenovirus Infection, and Gel Shift
Assay—Monocytes were isolated by counter-current centrifugal elutria-
tion of mononuclear leukocyte-rich cell preparations obtained from nor-
mal HIV-1 and hepatitis B seronegative donors after leukapheresis
(27). Monocytes were cultured as adherent monolayers for 2 days in the
presence of M-CSF (R & D Systems) and for a further 5 days in the
absence of cytokine before plating. Monocyte-derived macrophages were
infected 7 days after plating.
The parental adenovirus vector is a derivative of pJM17 (28) in
which the entire E1- and E3-coding sequences have been deleted. The
adenovirus shuttle vector (452/JL1) was constructed from pXC/JL1
(28). The HIV-1 Nef and green fluorescent protein (GFP)-coding re-
gions were inserted in the shuttle vector under control of the cyto-
megalovirus immediate early promoter. The recombinant GFP and
Nef adenovirus vectors were generated by homologous recombination
of the parent adenovirus vector with the corresponding shuttle vector
after calcium phosphate transfection of early passage 293 cells. Re-
combinants were propagated on 293 cells and purified through two
rounds of plaque purification and concentrated by cesium chloride
banding. Titers of recombinant viruses were determined by plaque
formation on 293 cells (29).
To prepare nuclear extracts from macrophages, cells were washed
twice with phosphate-buffered saline containing 1 mM Na3VO4 and 20
mM NaF and then lysed in buffer A (50 mM NaCl, 10 mM HEPES, pH
8.0, 500 mM sucrose, 1 mM EDTA, 0.5 mM spermidine, 0.15 mM sperm-
ine, 1 mM dithiothreitol, 0.2% Triton X-100). Nuclei were collected by
centrifugation at 6500 3 g for 3 min at 4 °C, washed in 600 ml of buffer
B (buffer A without Triton X-100), and collected again. Nuclear proteins
were extracted at 4 °C on a rotating wheel for 30 min in buffer C (350
mM NaCl, 10 mM HEPES, pH 8.0, 25% glycerol, 0.1 mM EDTA, 0.5 mM
spermidine, 0.15 mM spermine). Protease and phosphatase inhibitors
were added to all buffers (20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1
mM phenylmethylsulfonyl fluoride, 100 mM leupeptin, 0.3 mM aprotinin,
10 mM tosylphenylalanyl chloromethyl ketone (TPCK), 800 mM 1-chloro-
3-tosylamido-7-amino-2-heptanone (TLCK), 10 mM bestatin, 1 mM pep-
statin, 10 mM MG132). Extracts were clarified by centrifugation at
6500 3 g for 5 min, and protein concentrations were determined by the
Bradford assay according to the manufacturer’s instructions (Bio-Rad).
For the gel shift assay, 100 ng of wild-type or mutant Stat3 double-
stranded oligonucleotide probes (Santa Cruz) were end-labeled with
polynucleotide kinase in the presence of 20 mCi of [g-32P]ATP (6000Ci/
mmol, PerkinElmer Life Sciences). After removal of free ATP, 1 ng of
labeled probe was incubated with 2 mg of nuclear proteins and 2 mg of
poly(dIzdC) in binding buffer (50 mM KCl, 4% glycerol, 20 mM HEPES,
pH 7.9, 1 mM dithiothreitol, 5 mM MgCl2, 1 mM spermidine, 0.85 mM
EDTA, and 0.17% Nonidet P-40) for 15 min. Bound proteins were
separated on a 5% polyacrylamide gel in 0.53 Tris-borate EDTA and
visualized by autoradiography.
RESULTS
Nef Induces Cytokine-independent Growth in the Human
Myeloid Leukemia Cell Line, TF-1—Previous work from our
laboratory has shown that co-expression of Nef and Hck in
Rat-2 fibroblasts induces cellular transformation (15). Hck is
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strongly expressed in macrophages (30–34), an important tar-
get cell for primate lentivirus infection (35, 36). To investigate
whether endogenous Hck is activated by Nef in cells of the
monocyte/macrophage lineage, we utilized the human myeloid
leukemia cell line, TF-1 (18). This cell line is dependent on
GM-CSF, IL-3, or erythropoietin for growth; removal of cyto-
kine induces growth arrest and programmed cell death. Upon
treatment with phorbol esters, TF-1 cells differentiate into
macrophages.
Recombinant retroviruses were used to establish populations
of TF-1 cells that stably express Nef (15, 16). After infection
with Nef retroviruses, cells were placed under G418 selection
in the presence or absence of GM-CSF. As shown in Fig. 1A, Nef
expression was readily detected in the G418-resistant cells. To
our surprise, TF-1 cells expressing Nef no longer required
GM-CSF for growth (Fig. 1B). Whereas cells infected with a
control retrovirus did not survive in the absence of GM-CSF,
the TF-1 cells expressing Nef readily emerged from G418 se-
lection in the absence of cytokine.
To confirm that Nef was producing a survival signal in TF-1
cells, we also performed soft-agar colony assays. TF-1 cells
were infected with recombinant Nef retroviruses, selected with
G418, and plated in soft agar in the presence or absence of
GM-CSF. As shown in Fig. 2A, both the parental and Nef-
expressing TF-1 cells readily formed colonies in the presence of
GM-CSF. However, TF-1 cells expressing Nef also formed soft
agar colonies in the absence of cytokine, whereas the parental
cells did not. Immunoblot analysis of protein extracts from
parallel liquid cultures shows that Nef protein levels were
unchanged 24 h after GM-CSF removal, indicating that Nef
expression is independent of GM-CSF treatment (Fig. 2B).
GM-CSF-independent outgrowth of TF-1 cells expressing Nef
results from suppression of apoptosis as determined by flow
cytometry of propidium iodide-stained cells as well as DNA
fragmentation assays (data not shown). These results indicate
that Nef is sufficient to initiate a signal transduction event in
TF-1 cells permissive for survival in the absence of cytokine.
Induction of Cytokine-independent Growth in TF-1 Cells Re-
quires the Nef SH3 Binding Motif and Myristylation Signal
Sequence—We next investigated the structural features of Nef
that are required for the induction of cytokine independence by
Nef in TF-1 cells. For these experiments, we employed a Nef
mutant in which the N-terminal Gly residue essential for my-
ristylation is replaced with Ala (Nef-GA mutant). This muta-
tion blocks Nef myristylation, which is essential for membrane
targeting. We also tested a Nef mutant lacking the highly
conserved PXXP repeat essential for interaction with the Hck
SH3 domain (Nef-PA mutant). TF-1 cells expressing these Nef
mutants were tested for outgrowth in liquid culture as well as
colony-forming activity in soft agar in the presence or absence
of GM-CSF. As shown in Figs. 1 and 2, neither of these Nef
mutants was able to induce GM-CSF independence despite
strong expression of the mutant proteins. These results indi-
cate that both myristylation and the SH3 binding motif are
required for cytokine independence. Thus, the TF-1 cellular
target responsible for the Nef survival signal is likely to be a
membrane-localized protein with an SH3 domain.
Activation of Endogenous Hck by Nef in TF-1 Cells—Previous
studies have shown that Hck and other members of the Src
tyrosine kinase family are activated in response to GM-CSF,
IL-3, and/or erythropoietin (37–41), the three cytokines known
to promote survival of TF-1 cells (18). In addition, the SH3
domain of Hck binds to Nef with high affinity, leading to Hck
kinase activation both in vitro and in vivo (10, 11, 15, 16, 42).
These findings suggest that Nef may activate endogenous Hck
in TF-1 cells as part of a signaling pathway leading to cytokine-
independent growth. To determine whether Nef activates en-
dogenous Hck, control and Nef-expressing TF-1 cells were
washed free of GM-CSF and lysed, and Hck was immunopre-
FIG. 1. Expression of HIV-1 Nef promotes cytokine-independ-
ent outgrowth of the human GM-CSF-dependent myeloid leuke-
mia cell line, TF-1. A, stable expression of Nef and Nef mutants in
TF-1 cells. TF-1 cells were infected with recombinant retroviruses car-
rying wild-type Nef (WT), Nef mutants with alanine substitutions for
prolines 72 and 75 in the SH3-binding motif (PA), or with an alanine
substitution for glycine 2 in the myristylation signal sequence (GA).
Control cells (Con) were infected with an empty retrovirus carrying only
the neo selection marker. Cells were selected with G418 in the presence
of GM-CSF, and Nef protein expression was verified by immunoblot-
ting. Nef expression was also verified in TF-1 cells that emerged after
infection with the wild-type Nef retrovirus and withdrawal of GM-CSF
(far right lane). B, Nef promotes GM-CSF-independent outgrowth of
TF-1 cells. Triplicate cultures of TF-1 cells expressing wild-type Nef
(l), Nef-PA (f), Nef-GA (), or control cells ( l ) were washed and
replated at 1.25 3 105 cells/ml in the absence of GM-CSF. Viable cells
were counted with a hemocytometer every other day for 10 days. Re-
sults shown are the mean cell counts 6 S.E.
FIG. 2. HIV-1 Nef induces cytokine-independent colony forma-
tion in TF-1 cells. A, human TF-1 cells were infected with recombi-
nant retroviruses carrying wild-type Nef (WT) or the Nef SH3 binding
(PA) or myristylation-defective (GA) mutants as described in the legend
to Fig. 1. TF-1 cells were also infected with the parent retrovirus
carrying only the neo selection marker as a negative control (Con). Cells
were selected with G418 in the presence of GM-CSF and plated in soft
agar in the presence (1) or absence (2) of GM-CSF. After incubation for
14 days, colonies were photographed under the microscope. This exper-
iment was repeated in triplicate and revealed that nearly the same
numbers of colonies were obtained with TF-1 cells expressing Nef in the
presence or absence of GM-CSF (data not shown). B, immunoblot anal-
ysis of Nef expression of the TF-1 cultures used in A. Whole cell protein
extracts were prepared from TF-1 cultures maintained in the presence
of GM-CSF (1 GM, right) or 24 h after GM-CSF withdrawal (2 GM,
left). The arrow indicates the position of Nef on the blot.
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cipitated and assayed in vitro with [g-32P]ATP and a glutathi-
one S-transferase-Sam 68 fusion protein (p50) as substrate. As
shown in Fig. 3, TF-1 cells expressing Nef showed a greater
than 3-fold increase in endogenous Hck kinase activity relative
to control cells. These results suggest that activation of endog-
enous Hck may contribute to the survival effects of Nef in TF-1
cells. Similar levels of Hck activation have been observed after
stimulation of other myeloid leukemia cell lines with IL-3 (39)
or cross-linking of cell-surface Fc receptors (43). In contrast to
Hck, Fyn tyrosine kinase activity was not increased by the
presence of Nef in TF-1 cells (data not shown). This result is
consistent with the observation that the Fyn SH3 domain binds
to Nef in vitro with low affinity (11, 44).
We also investigated the activity of Hck in TF-1 cells express-
ing the Nef-PA and Nef-GA mutants. As shown in Fig. 3,
Nef-PA was unable to induce endogenous Hck activation in
TF-1 cells, indicating that the Nef SH3 binding motif is essen-
tial for kinase activation. This result is consistent with our
previous work in Rat-2 fibroblasts co-expressing Nef and Hck
(15, 16). On the other hand, mutagenesis of the myristylation
signal sequence did not markedly impair the ability of Nef to
induce Hck activation despite the myristylation requirement
for the induction of cytokine independence by Nef. Because the
Nef-GA mutant retains a functional SH3 binding motif, it is
possible that this mutant interacts with the cytoplasmic pool of
Hck (45, 46), resulting in kinase activation. However, activa-
tion of Hck at the plasma membrane may be required for
initiation of the signaling response required for cytokine
independence.
Nef Induces Activation of Endogenous Stat3 in GM-CSF-
independent TF-1 Cells—As an alternative test for the activa-
tion of endogenous tyrosine kinase signaling in TF-1 cells by
Nef, we investigated activation of the transcription factor,
Stat3. Stat3 is one member of a family of transcription factors
with SH2 domains that require tyrosine phosphorylation for
activation (47, 48). Tyrosine phosphorylation induces Stat
dimerization by reciprocal SH2-phosphotyrosine interaction,
leading to nuclear translocation, DNA binding, and gene acti-
vation. Thus, Stat activation is a good indicator of endogenous
tyrosine kinase activity.
Stat3 activation was investigated in TF-1 cells using an
electrophoretic mobility shift (gel-shift) assay with an oligonu-
cleotide probe based on the SIE, which is potently bound by
activated Stat3 (23, 25). As shown in Fig. 4, nuclear extracts
prepared from the GM-CSF-independent TF-1/Nef cells pro-
duced a strong shift in SIE mobility. The gel-shifted complex
was significantly reduced in control cells or in cells expressing
either the SH3 binding or myristylation-defective mutants of
Nef, which do not produce cytokine independence. SIE-protein
complex formation was completely blocked in the presence of a
100-fold excess of unlabeled probe, indicative of specific DNA
binding. No complexes were observed with a mutant SIE probe
lacking nucleotides critical for Stat3 binding, and addition of
anti-Stat3 antibodies to the reaction mixture completely inhib-
ited complex formation (data not shown). Treatment of control
TF-1 cells with GM-CSF produced a gel-shifted complex with
electrophoretic mobility identical to that observed with the
factor-independent TF-1/Nef cells, consistent with other data
showing that GM-CSF induces Stat3 activation in this cell line
(49). Taken together, these results demonstrate that Nef ex-
pression leads to the activation of endogenous Stat3 in TF-1
cells.
Direct Activation of Stat3 by Hck in a Heterologous Expres-
sion System—Data presented so far have demonstrated a
strong correlation between Nef-induced cytokine independence
and endogenous Hck and Stat3 activation. These results led us
to speculate that Hck may be the kinase responsible for Stat
activation downstream of Nef. To test this idea more directly,
we expressed Hck and Stat3 either alone or together in 293T
cells and assayed Stat3 activation using the gel-shift assay. As
shown in Fig. 5A, co-expression of Hck and Stat3 in 293T cells
produced a dramatic shift in probe mobility, indicative of po-
tent Stat3 activation. In contrast, expression of either protein
alone was without effect, consistent with the direct activation
of Stat3 by Hck in this system. As an additional negative
control, we co-expressed Stat3 with a kinase-inactive mutant of
Hck in this system. No gel-shift response was detected, dem-
onstrating the requirement for tyrosine phosphorylation in the
FIG. 3. Nef activates endogenous Hck in TF-1 cells. Endogenous
Hck proteins were immunoprecipitated from protein extracts of TF-1
cells stably expressing wild-type Nef (WT), mutant forms of Nef lacking
the SH3 binding function (PA), or the myristylation signal sequence
(GA) and from vector control cells (Con) and incubated in vitro with
[g-32P]ATP and a glutathione S-transferase-Sam 68 fusion protein of 50
kDa (p50) as substrate. After incubation, phosphorylated p50 was re-
solved by SDS-polyacrylamide gel electrophoresis and visualized by
quantitative storage phosphorimaging (upper panel). The relative ex-
tent of p50 phosphorylation is shown in the bar graph (middle). The
levels of the p59 and p61 forms of Hck present in each immunoprecipi-
tate were determined by immunoblotting (bottom). Phosphoamino acid
analysis verified the phosphorylation of p50 on tyrosine residues (data
not shown).
FIG. 4. Activation of endogenous Stat3 DNA binding activity
by Nef in TF-1 cells. Nuclear extracts were prepared from TF-1 cells
expressing wild-type Nef (WT), mutant forms of Nef lacking the SH3
binding function (PA), or the myristylation signal sequence (GA) or from
vector control cells (Con) as described under “Experimental Proce-
dures.. Extracts were tested for the presence of activated Stat3 by
gel-shift analysis with an SIE probe. To control for the specificity of
DNA binding, assays were performed in the presence (1) or absence (2)
of a 100-fold molar excess of unlabeled SIE oligonucleotide. As a positive
control, gel-shift assays were conducted on extracts from uninfected
TF-1 cells treated with (1) or without (2) GM-CSF. The positions of the
shifted Stat3zSIE complex and the free probe (FP) are indicated by the
arrows. Control immunoblots revealed equivalent levels of Stat3 in each
of the cellular extracts (data not shown).
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activation mechanism. Finally, we also tested a transforming
variant of Hck in which the negative regulatory tyrosine resi-
due in the C-terminal tail (Tyr-501) has been converted to Phe
(15). This Hck mutant activated Stat3 to the same extent as
wild type, suggesting that 293T cells lack sufficient Csk for
effective negative regulation of wild-type Hck. Csk is the kinase
responsible for the negative regulation of Src family kinases
and works by phosphorylating the conserved tyrosine residue
in Src family kinase C-terminal tails. As a result, the phospho-
rylated tail engages the SH2 domain in an intramolecular
fashion, contributing to kinase down-regulation.
To establish that Stat3 DNA binding activity induced by Hck
correlated with Stat3 tyrosine phosphorylation, lysates from
the transfected 293T cells were immunoblotted with anti-phos-
photyrosine antibodies. Fig. 5B shows that Stat3 is strongly
phosphorylated on tyrosine when co-expressed with either of
the active forms of Hck, consistent with the gel-shift result. In
contrast, lysates from cells expressing Stat3 alone or in the
presence of the kinase-inactive form of Hck showed no evidence
of Stat3 tyrosine phosphorylation. Control immunoblots show
that approximately equivalent levels of Stat3 and Hck proteins
were expressed. These results provide strong evidence that Hck
can induce direct activation of Stat3 under defined conditions
and suggest that Nef may trigger Stat3 activation via Hck in
TF-1 cells.
Activation of Stat3 Is Required for Nef-induced Survival of
TF-1 Cells—To determine whether activation of Stat3 is nec-
essary for Nef-induced cell survival, we employed two domi-
nant-negative mutants of Stat3. The first mutant (YF) lacks
the site of tyrosine phosphorylation (Tyr-705), whereas the
second (EVA) has mutations in Glu residues required for DNA
binding. These and related Stat3 mutants have been used to
block Stat3-mediated biological responses in other systems
(50–52) including transformation of fibroblasts by v-Src (53,
54). TF-1 cells were co-infected with recombinant retroviruses
carrying Nef and the dominant-negative Stat3 mutants. Nef
and the Stat3 mutants were linked to different drug selection
markers (neo and hygromycin, respectively) to ensure that cells
were infected with both retroviruses after double selection.
Drug-resistant cells were then plated in soft agar and scored
for colony outgrowth in the absence of GM-CSF. Nef readily
induced colony formation in cells that were also infected with a
control retrovirus carrying only the hygromycin resistance
marker (Fig. 6). However, when cells were doubly infected with
Nef and either of the Stat3 dominant-negative mutants, no
colony outgrowth was observed. These data suggest that acti-
vation of Stat3 is an essential part of the survival response
induced by Nef in TF-1 cells.
Nef Activates Stat3 in Primary Human Macrophages—A fi-
nal series of experiments investigated whether Nef can induce
Stat3 activation in primary human monocyte-derived macro-
phages, a target cell for HIV infection. For these experiments,
recombinant adenovirus vectors were used to introduce Nef
into primary cultures of macrophages isolated from normal
donors. Parallel cultures were infected with a control adenovi-
rus carrying GFP. Nuclear protein extracts were prepared from
Nef-infected and control macrophages and analyzed for the
presence of activated Stat3 using the SIE probe. As shown in
Fig. 7A, extracts from macrophages infected with the Nef ade-
novirus produced a marked shift in SIE mobility, whereas
extracts from control cells infected with the GFP adenovirus or
mock-infected cells had no effect. Duplicate gel shift assays
using an SIE probe with mutations in the sequence required for
Stat3 binding produced no detectable protein-DNA complexes.
Similarly, the addition of an excess of unlabeled SIE probe to
FIG. 5. Activation of Stat3 by Hck in 293T cells. Human 293T
cells were transfected with Stat3, wild-type Hck (WT), kinase-inactive
Hck (KE), or a Hck mutant with a Phe substitution for the conserved
tail Tyr residue (YF) either alone or in the combinations shown. A,
gel-shift assay. Cytosolic extracts were prepared and tested for the
presence of active Stat3 using a gel-shift assay and an SIE probe.
Extracts from cells transfected with the empty vector were included as
an additional negative control (Con). To control for the specificity of
DNA binding, assays were performed in the presence (1) or absence (2)
of a 100-fold molar excess of unlabeled SIE probe. The positions of the
shifted Stat3zSIE complex and the free probe (FP) are indicated by the
arrows. B, Stat3 tyrosine phosphorylation. Transfected 293T cell ly-
sates were immunoblotted with antibodies to phosphotyrosine (P-Tyr,
top), Stat3 (middle), or Hck (bottom). The arrows indicate the positions
of Stat3 and Hck.
FIG. 6. Suppression of Nef-induced TF-1 cell colony formation
by dominant-negative mutants of Stat3. TF-1 cells were infected
with recombinant retroviruses carrying Stat3 mutants lacking either
the tyrosine phosphorylation site (Stat3 YF) or glutamic acid residues
essential for DNA binding (Stat3 EVA). As a control, cells were infected
with a virus carrying the hygromycin selection marker alone (Vector).
Twenty-four hours later, the cells were superinfected with the Nef
retrovirus (linked to the neo selection marker) and selected with hygro-
mycin and G418 in the presence of GM-CSF. Drug-resistant cells were
plated in soft agar in the presence of hygromycin and G418 and in the
absence of GM-CSF. Macroscopic colonies were stained and counted
after 14 days. The experiment was plated in triplicate, and the average
number of colonies is shown 6S.E.
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the reaction completely inhibited formation of the gel-shifted
complex, whereas the mutant SIE did not (Fig. 7B). These
results are consistent with the observations made in TF-1 cells
after expression of Nef (Fig. 4) and provide direct evidence that
Nef expression is sufficient to activate both tyrosine kinase
activity and Stat3 in primary macrophages.
DISCUSSION
Previous work from our laboratory established that SH3-
mediated interaction of Nef with Hck is sufficient to induce
oncogenic transformation when these proteins are co-expressed
in Rat-2 fibroblasts (15–17). This result suggested that Nef
may constitutively induce Hck activation in target cells for HIV
that express this Src-related kinase, such as macrophages. In
this study, we provide evidence that Nef can induce endoge-
nous Hck activation in the monocyte/macrophage precursor cell
line, TF-1. Expression of Nef in TF-1 cells also revealed a new
biological property of Nef: its ability to induce cytokine-inde-
pendent myeloid cell growth. This finding suggests that Nef is
able to stimulate some of the signal transduction pathways
normally activated by GM-CSF that lead to survival and pro-
liferation in this cell line. Several observations suggest that
activation of Hck may contribute to the effect of Nef on TF-1
cell survival. First, Nef-induced activation of Hck (Fig. 3) but
not Fyn (data not shown) in the factor-independent cells corre-
lates with the binding affinities of Nef for the SH3 domains of
these Src family kinases (11, 44). Second, the Nef mutant lacking
the polyproline motif responsible for SH3 binding does not pro-
duce the cytokine-independent phenotype in TF-1 cells (Figs. 1
and 2) and is unable to activate endogenous Hck in these cells
(Fig. 3). In previous work, we and others show that the Nef SH3
binding motif is essential for interaction with Hck and subse-
quent kinase activation (10, 15). Finally, Hck is normally acti-
vated downstream of cytokine receptors, including those for GM-
CSF and IL-3 (38–40). Both of these cytokines have been shown
to promote growth and survival of TF-1 cells (18).
Previous work has established that Nef may mimic the effect
of IL-2 on T-lymphocyte activation (55). This study employed a
monkey T-lymphoid cell line, known as 221, which requires
IL-2 to proliferate. SIV was found to replicate efficiently in
IL-2-stimulated 221 cells independently of the presence of Nef.
However, nef1 viruses replicated as much as 100-fold more
efficiently than nef-defective viruses in the absence of IL-2.
This difference was attributed to the ability of Nef to induce
IL-2 production in the host cell line. These results suggest that
our observation of Nef-induced survival in myeloid cells may
also involve an autocrine mechanism, possibly through the
induction of GM-CSF, IL-3, or other cytokines known to pro-
mote TF-1 cell survival. However, we found that culture me-
dium conditioned by cytokine-independent TF-1/Nef cells was
unable to support naive TF-1 cell growth (data not shown).
Thus, Nef appears to promote TF-1 cell survival via constitu-
tive stimulation of a host survival pathway rather than
through the induction of anti-apoptotic cytokines.
The observation that Nef-induced activation of Hck corre-
lates with cytokine-independent survival of TF-1 cells suggests
that activation of Hck alone may be sufficient to induce the
survival response. We have tested this possibility by expressing
two different constitutively activated forms of Hck in TF-1 cells
using recombinant retroviruses. The first of these was acti-
vated by Phe substitution of the conserved Tyr residue in the
C-terminal tail, whereas the second has mutations of two pro-
line residues in the SH2-kinase linker region that interact
intramolecularly with the SH3 domain in the inactive form of
the kinase (15, 16). Although both of these mutants are
strongly transforming in Rat-2 fibroblasts, neither was able to
produce cytokine-independent outgrowth of TF-1 cells. This
result suggests that activation of Hck alone may not be suffi-
cient to produce the survival signal. Nef may activate other
members of the Src kinase family, which could in turn contrib-
ute to Stat activation and the observed biological effect. One
possibility is Lyn, which has been shown to mediate the GM-
CSF signal for survival in neutrophils (56). The Lyn SH3 do-
main has been shown to interact with Nef in vitro (10), sug-
gesting that Nef may induce Lyn activation in a manner
analogous to Hck. However, we have observed that co-expres-
sion of Lyn with Nef in fibroblasts does not induce Lyn activa-
tion under conditions where Hck is potently activated by Nef
(17). This result argues against a contribution of Lyn to the
observed survival signal produced by Nef in TF-1 cells. Alter-
natively, Nef-mediated activation of serine/threonine kinases
may be required for full transcriptional activation of Stat3 (57).
Nef has been recently shown to activate the c-Jun N-terminal
kinase (Jnk) downstream of Nak (58), a Pak-related kinase
that interacts directly with Nef (59, 60). Interestingly, Jnk and
the related p38 kinase have recently been identified as the
activities responsible for serine phosphorylation and transcrip-
tional activation of Stat3 in v-Src-transformed fibroblasts (61).
Thus it is possible that Nef may activate multiple kinase sig-
nals that are convergent on Stat3.
Data presented here show for the first time that expression
of HIV Nef is sufficient to activate a Stat signal transduction
pathway. Data in Fig. 4 demonstrate that Nef activates Stat3
DNA binding activity to the same extent as GM-CSF treatment
in TF-1 cells. Stat3 activation is required for the generation of
survival signals by Nef, as two different dominant-negative
Stat3 mutants were able to interfere with cytokine-independ-
ent colony formation (Fig. 6). This result agrees with the work
of Fukada et al. (50), who demonstrate that Stat3 dominant-
negative mutants were able to interfere with survival signals
generated by gp130, the signal-transducing receptor subunit
shared by the IL-6 family of cytokines. Hck has been implicated
in leukemia inhibitory factor signal transduction, which is
linked to gp130 (62, 63). Data presented in Fig. 5 show that Hck
can directly induce Stat3 DNA binding activity and tyrosine
phosphorylation in a defined expression system (293T cells).
FIG. 7. Nef activates endogenous Stat3 in human macro-
phages. Primary cultures of macrophages were infected with recombi-
nant adenovirus vectors carrying Nef (Ad-Nef) or green fluorescent
protein (Ad-GFP) cDNAs. Mock-infected cells were also included as an
additional negative control. A, nuclear extracts were prepared and
tested for the presence of activated Stat3 by gel-shift analysis with
wild-type or mutant (m) SIE probes. B, to control for specificity in the
gel-shifted complexes, duplicate assays were conducted in the presence
(1) of an excess of unlabeled wild-type or mutant SIE probes. The
arrows indicate the presence of the gel-shifted complexes.
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These results are consistent with the possibility that activation
of Hck by Nef may be sufficient to induce Stat3 tyrosine phos-
phorylation in TF-1 cells. In addition, a recent study has shown
that Src kinases, and not Jaks, are responsible for Stat activa-
tion in response to IL-3 treatment in some cases (64). More
recent work has shown that constitutive activation of Stat3
suppresses apoptosis in human multiple myeloma cells (65).
This study also demonstrated the Stat3-dependent induction of
the Bcl-2 family member Bcl-XL as a possible mechanism for
the observed anti-apoptotic effects of Stat3. Whether a similar
mechanism accounts for the Nef-induced survival of TF-1 cells
will require further investigation.
In addition to the TF-1 cell line, we observed that Nef ex-
pression is sufficient to activate Stat3 in primary human
macrophages, raising the possibility that Nef may mimic cyto-
kine signaling in this target cell for HIV. Although the biolog-
ical significance of this effect is currently unknown, it is rea-
sonable to speculate that Nef may contribute to macrophage
survival by a mechanism similar to that observed with TF-1
cells. Interestingly, HIV-1 infection of primary human macro-
phages promotes their survival in culture.2 Because Hck is a
myeloid-restricted tyrosine kinase, constitutive activation of a
Hck-Stat3 pathway by Nef may promote virus replication and
dissemination. Recently, it was demonstrated that monocyto-
tropism promotes amplification and spread of SIV in macaques
(36). This finding raises the possibility that Nef modifies the
physiology of macrophages in a way that promotes their role as
persistent viral reservoirs. Our observation that Nef may serve
as a survival factor is consistent with this role. The identifica-
tion of cellular pathways through which Nef mediates survival
and other effects may shed further light on the role of this
accessory gene product in virus replication and pathogenicity.
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